Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00999518 · ClinicalTrials.gov registry record · Phase 2
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
NCT00999518 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 205 participants.
The verdict
NCT00999518, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
Study Summary
In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary urgency. Only one dose was studied, and tanezumab was well tolerated. In this study, the hypothesis being tested is that tanezumab will show efficacy at several doses on reducing pain with sufficient tolerability. Tanezumab's safety will also be assessed at different dose levels
Interventions
- OTHER Placebo
- BIOLOGICAL Tanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2010-01-22 |
| Est. Completion | 2011-01-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00999518
The ClinicalTrials.gov registry entry for NCT00999518 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00999518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00999518 about?
NCT00999518 is a clinical study titled "A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome". In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary urgency. Only one dose was studied, and tanezumab was well tolerated. In this ...
What is the current status of trial NCT00999518?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2010-01-22. Estimated completion is 2011-01-21.
What interventions are being tested in trial NCT00999518?
The interventions under investigation include: Placebo (OTHER), Tanezumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00999518?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.